Healio: Targeting Obesity may be ‘Highly Effective Strategy’ for Treating HFpEF, ASCVD

At the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease, Mikhail Kosiborod, MD, FACC, FAHA, vice president of research at Saint Luke’s Mid America Heart Institute and professor of medicine at the University of Missouri-Kansas City School of Medicine, discussed four CV outcome trials that were presented in 2023. 

Among the trials discussed were the STEP-HFpEF and SELECT trials, both of which showed the GLP-1 receptor agonist semaglutide (Ozempic/Wegovy, Novo Nordisk) could provide CV benefits for adults with obesity.

Read the full article from Healio: Targeting Obesity may be ‘Highly Effective Strategy’ for Treating HFpEF, ASCVD

Related Content

Dec. 15, 2023

Science’s 2023 Breakthrough of the Year: Weight Loss Drugs with a Real Shot at Fighting Obesity
Presented by the lead author Mikhail Kosiborod, MD, the STEP-HFpEF trial is recognized by Science Magazine as Breakthrough of the Year throughout all science.
Dec. 29, 2023

AHA Names Top Advances in Cardiovascular Disease Research for 2023
The groundbreaking STEP-HFpEF study, led by Mikhail Kosiborod, MD, vice president of research at Saint Luke's Health System, has been named one of the top advances by the American Heart Association.